Versant Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$303 Buy
+5
New +$351 ﹤0.01% 2778
2025
Q2
– Sell
-11
Closed -$115 – 2701
2025
Q1
$115 Hold
11
– – ﹤0.01% 2484
2024
Q4
$157 Hold
11
– – ﹤0.01% 2342
2024
Q3
$220 Hold
11
– – ﹤0.01% 1956
2024
Q2
$210 Hold
11
– – ﹤0.01% 1900
2024
Q1
$158 Hold
11
– – ﹤0.01% 1846
2023
Q4
$95 Sell
11
-39
-78% -$295 ﹤0.01% 1898
2023
Q3
$448 Hold
50
– – ﹤0.01% 1713
2023
Q2
$433 Hold
50
– – ﹤0.01% 1864
2023
Q1
$478 Sell
50
-148
-75% -$4.48K ﹤0.01% 1588
2022
Q4
$6.7K Buy
198
+121
+157% +$5.86K ﹤0.01% 793
2022
Q3
$4K Buy
77
+28
+57% +$1.67K ﹤0.01% 912
2022
Q2
$3K Buy
49
+13
+36% +$820 ﹤0.01% 1009
2022
Q1
$3K Buy
36
+35
+3,500% +$5.18K ﹤0.01% 1049
2021
Q4
$0 Hold
1
– – ﹤0.01% 1539
2021
Q3
$0 Hold
1
– – ﹤0.01% 1544
2021
Q2
$0 Hold
1
– – ﹤0.01% 1548
2021
Q1
$0 Hold
1
– – ﹤0.01% 1574
2020
Q4
$0 Hold
1
– – ﹤0.01% 1467
2020
Q3
$0 Hold
1
– – ﹤0.01% 1433
2020
Q2
$0 Hold
1
– – ﹤0.01% 1470
2020
Q1
$0 Sell
1
-2
-67% -$619 ﹤0.01% 1554
2019
Q4
$1K Hold
3
– – ﹤0.01% 1252
2019
Q3
$0 Sell
3
-2
-40% -$733 ﹤0.01% 1518
2019
Q2
$2K Sell
5
-11
-69% -$5.52K ﹤0.01% 1194
2019
Q1
$8K Sell
16
-48
-75% -$28.4K ﹤0.01% 985
2018
Q4
$31K Sell
64
-6
-9% -$3.62K 0.01% 372
2018
Q3
$63K Sell
70
-58
-45% -$49.5K 0.03% 234
2018
Q2
$93K Sell
128
-12
-9% -$13.8K 0.04% 162
2018
Q1
$223K Sell
140
-16
-10% -$20.6K 0.09% 94
2017
Q4
$139K Buy
156
+21
+16% +$12.4K 0.06% 121
2017
Q3
$48K Buy
135
+58
+75% +$18.1K 0.03% 265
2017
Q2
$22K Buy
77
+29
+60% +$8.38K 0.01% 558
2017
Q1
$16K Buy
48
+47
+4,700% +$10.6K 0.01% 666
2016
Q4
$0 Sell
1
-3
-75% -$610 ﹤0.01% 1480
2016
Q3
$0 Hold
4
– – ﹤0.01% 1451
2016
Q2
$0 Hold
4
– – ﹤0.01% 1406
2016
Q1
$0 Hold
4
– – ﹤0.01% 1412
2015
Q4
$0 Buy
+4
New +$823 ﹤0.01% 1399

Other funds holding NKTR

Versant Capital Management's NKTR Position: Q3 2026 in Review

Versant Capital Management opened a new position in Nektar Therapeutics (NKTR) in Q3 2026: 5 shares worth $303. The stake represents ﹤0.01% of the portfolio and ranks #2778 among its holdings. This is a return to the name: Versant Capital Management previously reported a position in NKTR as recently as Q1 2025.

Versant Capital Management first reported a position in NKTR in Q4 2015 and has held it in 39 quarters since. The position peaked at $223K in Q1 2018. 243 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

  • Versant Capital Management held 5 shares of Nektar Therapeutics worth $303 as of Q3 2026.
  • Nektar Therapeutics was a new Versant Capital Management position in Q3 2026.
  • Nektar Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2778 holding.
  • Versant Capital Management first reported a position in Nektar Therapeutics in Q4 2015 and has held it in 39 quarters since.
  • Versant Capital Management's Nektar Therapeutics position peaked at $223K in Q1 2018.
  • 243 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.